The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
For Immediate Release
October 10, 2014
Release
The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infecti on. It is also the first approved regimen that does not require administration with interferon or
Source: Nelson Vergel's HIV Blog - Category: Infectious Diseases Authors: Anonymous Source Type: blogs
More News: Blogging | Food and Drug Administration (FDA) | Hepatitis | Hepatitis C | Infectious Diseases